Modulators and methods of use

1. An isolated anti-CD46 antibody or immunoreactive fragment thereof, wherein the antibody or immunoreactive fragment thereof is selected from the group consisting of:

a) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 15 for CDR-H1, residues 50-65 of SEQ ID NO: 15 for CDR-H2, and residues 95-102 of SEQ ID NO: 15 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 17 for CDR-L1, residues 50-56 of SEQ ID NO: 17 for CDR-L2 and residues 89-97 of SEQ ID NO: 17 for CDR-L3, wherein the residues are numbered according to Kabat;

b) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 19 for CDR-H1, residues 50-65 of SEQ ID NO: 19 for CDR-H2, and residues 95-102 of SEQ ID NO: 19 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2 and residues 89-97 of SEQ ID NO: 21 for CDR-L3, wherein the residues are numbered according to Kabat;

c) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 25 for CDR-L1, residues 50-56 of SEQ ID NO: 25 for CDR-L2 and residues 89-97 of SEQ ID NO: 25 for CDR-L3, wherein the residues are numbered according to Kabat;

d) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2, and residues 95-102 of SEQ ID NO: 27 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 29 for CDR-L1, residues 50-56 of SEQ ID NO: 29 for CDR-L2 and residues 89-97 of SEQ ID NO: 29 for CDR-L3, wherein the residues are numbered according to Kabat;

e) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H1, residues 50-65 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H2, and residues 95-102 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 33 for CDR-L1, residues 50-56 of SEQ ID NO: 33 for CDR-L2 and residues 89-97 of SEQ ID NO: 33 for CDR-L3, wherein the residues are numbered according to Kabat;

f) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 35 for CDR-H1, residues 50-65 of SEQ ID NO: 35 for CDR-H2, and residues 95-102 of SEQ ID NO: 35 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 37 for CDR-L1, residues 50-56 of SEQ ID NO: 37 for CDR-L2 and residues 89-97 of SEQ ID NO: 37 for CDR-L3, wherein the residues are numbered according to Kabat;

g) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 39 for CDR-H1, residues 50-65 of SEQ ID NO: 39 for CDR-H2, and residues 95-102 of SEQ ID NO: 39 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 41 for CDR-L1, residues 50-56 of SEQ ID NO: 41 for CDR-L2 and residues 89-97 of SEQ ID NO: 41 for CDR-L3, wherein the residues are numbered according to Kabat;

h) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2, and residues 95-102 of SEQ ID NO: 43 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 45 for CDR-L1, residues 50-56 of SEQ ID NO: 45 for CDR-L2 and residues 89-97 of SEQ ID NO: 45 for CDR-L3, wherein the residues are numbered according to Kabat;

i) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 47 for CDR-H1, residues 50-65 of SEQ ID NO: 47 for CDR-H2, and residues 95-102 of SEQ ID NO: 47 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 49 for CDR-L1, residues 50-56 of SEQ ID NO: 49 for CDR-L2 and residues 89-97 of SEQ ID NO: 49 for CDR-L3, wherein the residues are numbered according to Kabat;

j) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 51 for CDR-H1, residues 50-65 of SEQ ID NO: 51 for CDR-H2, and residues 95-102 of SEQ ID NO: 51 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 53 for CDR-L1, residues 50-56 of SEQ ID NO: 53 for CDR-L2 and residues 89-97 of SEQ ID NO: 53 for CDR-L3, wherein the residues are numbered according to Kabat;

k) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 55 for CDR-H1, residues 50-65 of SEQ ID NO: 55 for CDR-H2, and residues 95-102 of SEQ ID NO: 55 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 57 for CDR-L1, residues 50-56 of SEQ ID NO: 57 for CDR-L2 and residues 89-97 of SEQ ID NO: 57 for CDR-L3, wherein the residues are numbered according to Kabat;

l) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 59 for CDR-H1, residues 50-65 of SEQ ID NO: 59 for CDR-H2, and residues 95-102 of SEQ ID NO: 59 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 61 for CDR-L1, residues 50-56 of SEQ ID NO: 61 for CDR-L2 and residues 89-97 of SEQ ID NO: 61 for CDR-L3, wherein the residues are numbered according to Kabat;

m) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 63 for CDR-H1, residues 50-65 of SEQ ID NO: 63 for CDR-H2, and residues 95-102 of SEQ ID NO: 63 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 65 for CDR-L1, residues 50-56 of SEQ ID NO: 65 for CDR-L2 and residues 89-97 of SEQ ID NO: 65 for CDR-L3, wherein the residues are numbered according to Kabat;

n) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 67 for CDR-H1, residues 50-65 of SEQ ID NO: 67 for CDR-H2, and residues 95-102 of SEQ ID NO: 67 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 69 for CDR-L1, residues 50-56 of SEQ ID NO: 69 for CDR-L2 and residues 89-97 of SEQ ID NO: 69 for CDR-L3, wherein the residues are numbered according to Kabat;

o) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 71 for CDR-H1, residues 50-65 of SEQ ID NO: 71 for CDR-H2, and residues 95-102 of SEQ ID NO: 71 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 73 for CDR-L1, residues 50-56 of SEQ ID NO: 73 for CDR-L2 and residues 89-97 of SEQ ID NO: 73 for CDR-L3, wherein the residues are numbered according to Kabat;

p) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 75 for CDR-H1, residues 50-65 of SEQ ID NO: 75 for CDR-H2, and residues 95-102 of SEQ ID NO: 75 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 77 for CDR-L1, residues 50-56 of SEQ ID NO: 77 for CDR-L2 and residues 89-97 of SEQ ID NO: 77 for CDR-L3, wherein the residues are numbered according to Kabat;

q) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 79 for CDR-H1, residues 50-65 of SEQ ID NO: 79 for CDR-H2, and residues 95-102 of SEQ ID NO: 79 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 81 for CDR-L1, residues 50-56 of SEQ ID NO: 81 for CDR-L2 and residues 89-97 of SEQ ID NO: 81 for CDR-L3, wherein the residues are numbered according to Kabat;

r) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 83 for CDR-H1, residues 50-65 of SEQ ID NO: 83 for CDR-H2, and residues 95-102 of SEQ ID NO: 83 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 85 for CDR-L1, residues 50-56 of SEQ ID NO: 85 for CDR-L2 and residues 89-97 of SEQ ID NO: 85 for CDR-L3, wherein the residues are numbered according to Kabat;

s) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 199 for CDR-H1, residues 50-65 of SEQ ID NO: 199 for CDR-H2, and residues 95-102 of SEQ ID NO: 199 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 201 for CDR-L1, residues 50-56 of SEQ ID NO: 201 for CDR-L2 and residues 89-97 of SEQ ID NO: 201 for CDR-L3, wherein the residues are numbered according to Kabat; and

t) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 203 for CDR-H1, residues 50-65 of SEQ ID NO: 203 for CDR-H2, and residues 95-102 of SEQ ID NO: 203 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 205 for CDR-L1, residues 50-56 of SEQ ID NO: 205 for CDR-L2 and residues 89-97 of SEQ ID NO: 205 for CDR-L3, wherein the residues are numbered according to Kabat.

2. The isolated anti-CD46 antibody or immunoreactive fragment thereof according to claim 1 , wherein the antibody or immunoreactive fragment thereof is selected from the group consisting of:

a) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 15, and comprising a light chain variable region set forth as SEQ ID NO: 17;

b) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 18, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 20;

c) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 23, and comprising a light chain variable region set forth as SEQ ID NO: 25;

d) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 27, and comprising a light chain variable region set forth as SEQ ID NO: 29;

e) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 30, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 32;

f) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 35, and comprising a light chain variable region set forth as SEQ ID NO: 37;

g) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 39, and comprising a light chain variable region set forth as SEQ ID NO: 41;

h) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 42, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 44;

i) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 46, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 48;

j) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 51, and comprising a light chain variable region set forth as SEQ ID NO: 53;

k) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 55, and comprising a light chain variable region set forth as SEQ ID NO: 57;

l) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 59, and comprising a light chain variable region set forth as SEQ ID NO: 61;

m) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 63, and comprising a light chain variable region set forth as SEQ ID NO: 65;

n) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 67, and comprising a light chain variable region set forth as SEQ ID NO: 69;

o) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 70, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 72;

p) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 75, and comprising a light chain variable region set forth as SEQ ID NO: 77;

q) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 79, and comprising a light chain variable region set forth as SEQ ID NO: 81

r) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 83, and comprising a light chain variable region set forth as SEQ ID NO: 85;

s) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 199, and comprising a light chain variable region set forth as SEQ ID NO: 201; and

t) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 203, and comprising a light chain variable region set forth as SEQ ID NO: 205.

3. The isolated anti-CD46 antibody or immunoreactive fragment thereof according to claim 1 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is selected from the group consisting of monoclonal antibodies, chimeric antibodies, CDR-grafted antibodies, and humanized antibodies.

4. An isolated anti-CD46 antibody or immunoreactive fragment thereof comprising a heavy chain variable region set forth as SEQ ID NO: 199, and comprising a light chain variable region set forth as SEQ ID NO: 201.

5. An isolated anti-CD46 antibody or immunoreactive fragment thereof comprising a heavy chain variable region set forth as SEQ ID NO: 203, and comprising a light chain variable region set forth as SEQ ID NO: 205.

6. The isolated anti-CD46 antibody or immunoreactive fragment thereof according to claim 1 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is conjugated to a cytotoxic agent and optionally comprises a pharmaceutically acceptable carrier.

7. The isolated anti-CD46 antibody or immunoreactive fragment thereof according to claim 2 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is conjugated to a cytotoxic agent and optionally comprises a pharmaceutically acceptable carrier.

8. The isolated anti-CD46 antibody or immunoreactive fragment thereof according to claim 6 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof comprises a heavy chain variable region and light chain variable region selected from the group consisting of:

(a) a heavy chain variable region set forth as SEQ ID NO: 199, and comprising a light chain variable region set forth as SEQ ID NO: 201; and

(b) a heavy chain variable region set forth as SEQ ID NO: 203, and comprising a light chain variable region set forth as SEQ ID NO: 205.

9. A vector comprising a polynucleotide, wherein the polynucleotide encodes a polypeptide comprising a heavy chain variable region set forth as SEQ ID NO: 199 or SEQ ID NO: 203 or a light chain variable region set forth as SEQ ID NO: 201 or SEQ ID NO: 205.